Major Shareholder Atlas Venture Files to Sell $22M in Kymera Therapeutics Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (4.7× avg).
Summary
Atlas Venture Fund X, LP, a significant shareholder, has filed a Form 144 indicating its intent to sell approximately $22 million worth of Kymera Therapeutics common stock. This follows over $22 million in sales by Atlas Venture entities and an associated individual in the past three months.
Key Events · Ownership and Investor Activity · KYMR
-
Proposed Stock Sale
Atlas Venture Fund X, LP intends to sell 243,976 shares of common stock, valued at approximately $22.06 million, with an approximate sale date of June 22, 2026.
-
Recent Selling Activity
This proposed sale follows the disposition of 247,362 shares by Atlas Venture entities and an associated individual, generating over $22.41 million in gross proceeds, within the last three months.
-
Institutional Shareholder
The filer, Atlas Venture Fund X, LP, is a significant shareholder, and this filing is part of an ongoing pattern of Form 144 filings from this entity and related funds.
Analysis · KYMR · Life Sciences
This Form 144 filing signals a continued distribution of shares by Atlas Venture, a major institutional investor in Kymera Therapeutics. The proposed sale of over $22 million, combined with similar sales totaling over $22 million by Atlas Venture entities and an associated individual in the last three months, represents a substantial divestment by a key shareholder. While institutional selling can be for portfolio rebalancing, the consistent pattern and significant aggregate value could put downward pressure on the stock.
At the time of this filing, KYMR was trading at $99.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $36.65 to $105.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.